Allogene Therapeutics : J.P. Morgan Conference Presentation - January 2021

The Next Revolution in Cell Therapy

Leading Today, Creating Tomorrow

39th Annual J.P. Morgan Healthcare Conference

January 2021

Legal Disclaimers

To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: clinical outcomes, which may materially change as patient enrollment continues and more patient data become available, the timing and ability to progress the clinical trials of ALLO-501,ALLO-501A and ALLO-715, the timing and ability to initiate a clinical trial of ALLO-715 in combination with SpringWorks' nirogacestat and a clinical trial of ALLO-316, the timing and ability to file an IND and initiate a clinical trial of ALLO-605, the ability to manufacture AlloCAR T™ therapies for use in clinical trials, and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended September 30, 2020.

Caution should be exercised when interpreting results from separate trials involving separate product candidates. There are differences in the clinical trial design, patient populations, and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

2

The Allogene Vision

Create and lead the next revolution in cancer treatment by delivering to patients the first AlloCAR T™ therapies for blood cancers and solid tumors.

3

Allogene: Singular Focus on Allogeneic Cell Therapy

		SUCCESSFUL TRACK RECORD OF EXECUTION
2018
Manufacturing	Clinical Trial	Breaking Down	Demonstrating	Pipeline
Allogene	Experience	Execution	Allogeneic	Efficacy	Progress	2021
Launch				Hurdles

From launch to	Delivered	Leading the field	Controlling Graft	Complete Responses	5 clinical trials planned
leadership in less	uninterrupted	with 75+ patients	vs Host Disease	and Minimal Residual	in 2021, including:
than 3 years	supply for all	treated with	(GvHD) and	Disease (MRD)	1st pivotal trial
	clinical trials	AlloCAR T	AlloCAR T cell	responses observed
Raised $1.5B in			rejection		1st solid tumor trial
aggregate capital	Newark facility on	2 key Phase 1		Proof-of-Concept for	1st combo trial
	track to begin	datasets presented	Creating a	proprietary	1st TurboCAR trial
	production in 2021	in 2020 at major	window of cell	lymphodepletion
		medical meetings	persistence	platform

4